Sotabase

Career

· Researcher, UC Berkeley Berkeley Artificial Intelligence Research Lab (BAIR)2024–
· Fellow, FUSE Corps2016–
· Researcher, UC Berkeley2016–
· Urban Planning Trainee, UC Berkeley2016–

Publications (351)

Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma
JAMA Oncology · 2020
1,109
cited
Current state of immunotherapy for glioblastoma
Nature Reviews Clinical Oncology · 2018
1,084
cited
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.
The Lancet Oncology · 2017
869
cited
Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions.
Neuro-Oncology · 2020
868
cited
Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas.
International Journal of Radiation Oncology, Biology, Physics · 2013
850
cited
Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy.
The Lancet Oncology · 2015
766
cited
Mechanisms of immunotherapy resistance: lessons from glioblastoma
Nature Immunology · 2019
579
cited
Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma.
Neuro-Oncology · 2014
456
cited
Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143
Neuro-Oncology · 2018
425
cited
Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas
Clinical Cancer Research · 2016
398
cited
Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord
Proceedings of the National Academy of Sciences of the United States of America · 2015
380
cited
Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial
Neuro-Oncology · 2022
365
cited
Prospects of immune checkpoint modulators in the treatment of glioblastoma
Nature Reviews Neurology · 2015
356
cited
OS10.3 Randomized Phase 3 Study Evaluating the Efficacy and Safety of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: CheckMate 143
2017
303
cited
Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
International Journal of Radiation Oncology, Biology, Physics · 2017
292
cited
TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM
Oncoimmunology · 2018
277
cited
Anti–PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM
Science Translational Medicine · 2016
260
cited
Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden
Proceedings of the National Academy of Sciences of the United States of America · 2017
247
cited
Focal Radiation Therapy Combined with 4-1BB Activation and CTLA-4 Blockade Yields Long-Term Survival and a Protective Antigen-Specific Memory Response in a Murine Glioma Model
PLoS ONE · 2014
237
cited
A review of glioblastoma immunotherapy
Journal of Neuro-Oncology · 2020
228
cited
Sotabase
Michael Lim | Researcher Profile | Sotabase | Sotabase